BMRN - BioMarin Pharmaceutical Non-GAAP EPS of $0.46 misses by $0.02 revenue of $581.3M misses by $26.46M
2023-11-01 16:29:22 ET
More on BioMarin Pharmaceutical
- BioMarin: Growth Drivers Remain Intact
- BioMarin: Q2 2023 Confirmed My Bullish View
- BioMarin appoints Alexander Hardy as president and chief executive officer
- BioMarin Pharmaceutical Q3 2023 Earnings Preview
- Seeking Alpha’s Quant Rating on BioMarin Pharmaceutical
For further details see:
BioMarin Pharmaceutical Non-GAAP EPS of $0.46 misses by $0.02, revenue of $581.3M misses by $26.46M